AstraZeneca PLC and its subsidiary AstraZeneca Finance LLC on Sunday priced a €2.55 billion Eurobond offering, according to filings with the UK Financial Conduct Authority.
The issuance comprises four fixed-rate tranches maturing between March 2030 and September 2038, with coupon rates ranging from 3.402% to 4.169%. The largest tranche, €750 million, matures in 2038 at a coupon of 4.169%, while the shortest, €700 million, matures in March 2030 at 3.402%. The remaining tranches total €1.1 billion and carry coupons of 3.652% and 3.923% for maturities in 2032 and 2035, respectively.
Joint coordinators for the deal include Barclays Bank PLC, Goldman Sachs International, and Morgan Stanley. The notes are guaranteed by AstraZeneca PLC and will be admitted to the UK Financial Conduct Authority’s Official List and traded on the London Stock Exchange’s Main Market. Settlement is expected by September 1, 2026.
The company stated the proceeds will be used for general corporate purposes as part of its long-term financing strategy. The Eurobonds were issued under AstraZeneca’s Euro Medium Term Note program and are not registered under the U.S. Securities Act of 1933, restricting their sale in the United States without registration or an applicable exemption.
AstraZeneca, headquartered in Cambridge, UK, is a biopharmaceutical company focused on prescription medicines in oncology, rare diseases, and biopharmaceuticals.
